Demographic characteristics of mild to moderate Crohn's disease and ulcerative colitis in MarketScan, 2010–2014
| Crohn's disease N=7493 | Ulcerative colitis N=9566 | |
|---|---|---|
| Age at first IBD encounter, median (min–max) | 44 years (18–64) | 46 years (18–64) |
| 18–34 years | 27% | 22% |
| 35–49 years | 37% | 38% |
| 50–64 years | 36% | 40% |
| Female | 59% | 56% |
| Median length of follow-up after first IBD | 2.00 years | 2.00 years |
| encounter (min–max) | (1.00–4.99) | (1.00–4.99) |
| Total outpatient IBD visits* | ||
| 2–5 | 39.0% | 51.6% |
| 6–10 | 23.6% | 26.2% |
| >10 | 37.4% | 22.2% |
| Average number of IBD outpatient visits/year* | ||
| <2 | 28.1% | 38.9% |
| 2–5 | 35.7% | 40.7% |
| >5 | 36.3% | 20.4% |
| Smoker | 8.9% | 5.5% |
| Ever use of IBD-related medications | ||
| Biologic† | 25.6% | 8.7% |
| Immunomodulator‡ | 25.3% | 17.1% |
| Steroid | 45.8% | 45.6% |
| 5-ASA | 26.3% | 56.8% |
*IBD visits including acute care, emergency, laboratory and pathology encounters associated with an IBD diagnosis code.
†Biologic: infliximab, adalimumab, natalizumab, certolizumab.
‡Immunomodulator: 6-MP, azathioprine, cyclosporine, methotrexate.
IBD, inflammatory bowel disease.